Search Results - "HOLYOAKE, Tessa"

The chronic myeloid leukemia stem cell: stemming the tide of persistence by Holyoake, Tessa L., Vetrie, David

“…Chronic myeloid leukemia (CML) is caused by the acquisition of the tyrosine kinase BCR-ABL1 in a hemopoietic stem cell, transforming it into a leukemic stem…”
Get full text

Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib by Li, Ling, Wang, Lisheng, Li, Liang, Wang, Zhiqiang, Ho, Yinwei, McDonald, Tinisha, Holyoake, Tessa L., Chen, WenYong, Bhatia, Ravi

“…BCR-ABL tyrosine kinase inhibitors (TKI) fail to eliminate quiescent leukemia stem cells (LSC) in chronic myelogenous leukemia (CML). Thus, strategies…”
Get full text

Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells by Kuntz, Elodie M, Baquero, Pablo, Michie, Alison M, Dunn, Karen, Tardito, Saverio, Holyoake, Tessa L, Helgason, G Vignir, Gottlieb, Eyal

“…Treatment with tyrosine kinase inhibitors results in a survival benefit in patients with chronic myeloid leukemia (CML). However, relapse due to persistent…”
Get full text

Altered Microenvironmental Regulation of Leukemic and Normal Stem Cells in Chronic Myelogenous Leukemia by Zhang, Bin, Ho, Yin Wei, Huang, Qin, Maeda, Takahiro, Lin, Allen, Lee, Sung-uk, Hair, Alan, Holyoake, Tessa L., Huettner, Claudia, Bhatia, Ravi

“…We characterized leukemia stem cells (LSC) in chronic phase chronic myelogenous leukemia (CML) using a transgenic mouse model. LSC were restricted to cells…”
Get full text

Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt–β-catenin signaling by Zhang, Bin, Li, Min, McDonald, Tinisha, Holyoake, Tessa L., Moon, Randall T., Campana, Dario, Shultz, Leonard, Bhatia, Ravi

“…Tyrosine kinase inhibitors (TKIs) are highly effective in treatment of chronic myeloid leukemia (CML) but do not eliminate leukemia stem cells (LSCs), which…”
Get full text

Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor–treated CML stem cells by Zhang, Bin, Chu, Su, Agarwal, Puneet, Campbell, Victoria L., Hopcroft, Lisa, Jørgensen, Heather G., Lin, Allen, Gaal, Karl, Holyoake, Tessa L., Bhatia, Ravi

“…Treatment of chronic myelogenous leukemia (CML) with BCR-ABL tyrosine kinase inhibitors (TKI) fails to eliminate leukemia stem cells (LSC). Patients remain at…”
Get full text

Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia by Herrmann, Harald, Sadovnik, Irina, Cerny-Reiterer, Sabine, Rülicke, Thomas, Stefanzl, Gabriele, Willmann, Michael, Hoermann, Gregor, Bilban, Martin, Blatt, Katharina, Herndlhofer, Susanne, Mayerhofer, Matthias, Streubel, Berthold, Sperr, Wolfgang R., Holyoake, Tessa L., Mannhalter, Christine, Valent, Peter

“…Chronic myeloid leukemia (CML) is a stem cell (SC) neoplasm characterized by the BCR/ABL1 oncogene. Although mechanisms of BCR/ABL1-induced transformation are…”
Get full text

Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells by Abraham, Sheela A., Hopcroft, Lisa E. M., Carrick, Emma, Drotar, Mark E., Dunn, Karen, Williamson, Andrew J. K., Korfi, Koorosh, Baquero, Pablo, Park, Laura E., Scott, Mary T., Pellicano, Francesca, Pierce, Andrew, Copland, Mhairi, Nourse, Craig, Grimmond, Sean M., Vetrie, David, Whetton, Anthony D., Holyoake, Tessa L.

“…Chronic myeloid leukaemia (CML) arises after transformation of a haemopoietic stem cell (HSC) by the protein-tyrosine kinase BCR–ABL. Direct inhibition of…”
Get full text

Adult hematopoietic stem cells lacking Hif-1α self-renew normally by Vukovic, Milica, Sepulveda, Catarina, Subramani, Chithra, Guitart, Amélie V., Mohr, Jasmine, Allen, Lewis, Panagopoulou, Theano I., Paris, Jasmin, Lawson, Hannah, Villacreces, Arnaud, Armesilla-Diaz, Alejandro, Gezer, Deniz, Holyoake, Tessa L., Ratcliffe, Peter J., Kranc, Kamil R.

“…The hematopoietic stem cell (HSC) pool is maintained under hypoxic conditions within the bone marrow microenvironment. Cellular responses to hypoxia are…”
Get full text

BRD4-mediated repression of p53 is a target for combination therapy in AML by Latif, Anne-Louise, Newcombe, Ashley, Li, Sha, Gilroy, Kathryn, Robertson, Neil A., Lei, Xue, Stewart, Helen J. S., Cole, John, Terradas, Maria Terradas, Rishi, Loveena, McGarry, Lynn, McKeeve, Claire, Reid, Claire, Clark, William, Campos, Joana, Kirschner, Kristina, Davis, Andrew, Lopez, Jonathan, Sakamaki, Jun-ichi, Morton, Jennifer P., Ryan, Kevin M., Tait, Stephen W. G., Abraham, Sheela A., Holyoake, Tessa, Higgins, Brian, Huang, Xu, Blyth, Karen, Copland, Mhairi, Chevassut, Timothy J. T., Keeshan, Karen, Adams, Peter D.

“…Acute myeloid leukemia (AML) is a typically lethal molecularly heterogeneous disease, with few broad-spectrum therapeutic targets. Unusually, most AML retain…”
Get full text

CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy by Kinstrie, Ross, Horne, Gillian A., Morrison, Heather, Irvine, David, Munje, Chinmay, Castañeda, Eduardo Gómez, Moka, Hothri A., Dunn, Karen, Cassels, Jennifer E., Parry, Narissa, Clarke, Cassie J., Scott, Mary T., Clark, Richard E., Holyoake, Tessa L., Wheadon, Helen, Copland, Mhairi

“…The introduction of BCR-ABL tyrosine kinase inhibitors has revolutionized the treatment of chronic myeloid leukemia (CML). A major clinical aim remains the…”
Get full text

Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia by Zhang, Bin, Nguyen, Le Xuan Truong, Li, Ling, Zhao, Dandan, Kumar, Bijender, Wu, Herman, Lin, Allen, Pellicano, Francesca, Hopcroft, Lisa, Su, Yu-Lin, Copland, Mhairi, Holyoake, Tessa L, Kuo, Calvin J, Bhatia, Ravi, Snyder, David S, Ali, Haris, Stein, Anthony S, Brewer, Casey, Wang, Huafeng, McDonald, Tinisha, Swiderski, Piotr, Troadec, Estelle, Chen, Ching-Cheng, Dorrance, Adrienne, Pullarkat, Vinod, Yuan, Yate-Ching, Perrotti, Danilo, Carlesso, Nadia, Forman, Stephen J, Kortylewski, Marcin, Kuo, Ya-Huei, Marcucci, Guido

“…In chronic myelogenous leukemia, leukemia stem cell function requires a microRNA that is provided by bone marrow endothelial cells. Leukemia stem cells (LSCs)…”
Get full text

JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo by Gallipoli, Paolo, Cook, Amy, Rhodes, Susan, Hopcroft, Lisa, Wheadon, Helen, Whetton, Anthony D., Jørgensen, Heather G., Bhatia, Ravi, Holyoake, Tessa L.

“…Chronic myeloid leukemia (CML) stem cell survival is not dependent on BCR-ABL protein kinase and treatment with ABL tyrosine kinase inhibitors cures only a…”
Get full text

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival by Hamilton, Ashley, Helgason, G. Vignir, Schemionek, Mirle, Zhang, Bin, Myssina, Svetlana, Allan, Elaine K., Nicolini, Franck E., Müller-Tidow, Carsten, Bhatia, Ravi, Brunton, Valerie G., Koschmieder, Steffen, Holyoake, Tessa L.

“…Recent evidence suggests chronic myeloid leukemia (CML) stem cells are insensitive to kinase inhibitors and responsible for minimal residual disease in treated…”
Get full text

Concise Review: Cancer Cells Escape from Oncogene Addiction: Understanding the Mechanisms Behind Treatment Failure for More Effective Targeting by Pellicano, Francesca, Mukherjee, Leena, Holyoake, Tessa L.

“…Oncogene addiction describes the dependence of some cancers on one or a few genes for their survival. Inhibition of the corresponding oncoproteins can lead to…”
Get full text

Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML by Helgason, G. Vignir, Karvela, Maria, Holyoake, Tessa L.

“…The introduction of imatinib in the treatment of chronic myeloid leukemia (CML) represents the most successful example of targeted therapy in human cancer…”
Get full text

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells by Neviani, Paolo, Harb, Jason G, Oaks, Joshua J, Santhanam, Ramasamy, Walker, Christopher J, Ellis, Justin J, Ferenchak, Gregory, Dorrance, Adrienne M, Paisie, Carolyn A, Eiring, Anna M, Ma, Yihui, Mao, Hsiaoyin C, Zhang, Bin, Wunderlich, Mark, May, Philippa C, Sun, Chaode, Saddoughi, Sahar A, Bielawski, Jacek, Blum, William, Klisovic, Rebecca B, Solt, Janelle A, Byrd, John C, Volinia, Stefano, Cortes, Jorge, Huettner, Claudia S, Koschmieder, Steffen, Holyoake, Tessa L, Devine, Steven, Caligiuri, Michael A, Croce, Carlo M, Garzon, Ramiro, Ogretmen, Besim, Arlinghaus, Ralph B, Chen, Ching-Shih, Bittman, Robert, Hokland, Peter, Roy, Denis-Claude, Milojkovic, Dragana, Apperley, Jane, Goldman, John M, Reid, Alistair, Mulloy, James C, Bhatia, Ravi, Marcucci, Guido, Perrotti, Danilo

“…The success of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML) depends on the requirement for BCR-ABL1 kinase activity in CML…”
Get full text

Do we need more drugs for chronic myeloid leukemia? by Holyoake, Tessa L., Helgason, G. Vignir

“…Summary The introduction of protein tyrosine kinase inhibitors (TKIs) in 1998 transformed the management of chronic myeloid leukemia (CML), leading to…”
Get full text

CXCR2 and CXCL4 regulate survival and self-renewal of hematopoietic stem/progenitor cells by Sinclair, Amy, Park, Laura, Shah, Mansi, Drotar, Mark, Calaminus, Simon, Hopcroft, Lisa E.M., Kinstrie, Ross, Guitart, Amelie V., Dunn, Karen, Abraham, Sheela A., Sansom, Owen, Michie, Alison M., Machesky, Laura, Kranc, Kamil R., Graham, Gerard J., Pellicano, Francesca, Holyoake, Tessa L.

“…The regulation of hematopoietic stem cell (HSC) survival and self-renewal within the bone marrow (BM) niche is not well understood. We therefore investigated…”
Get full text

Targeting quiescent leukemic stem cells using second generation autophagy inhibitors by Baquero, Pablo, Dawson, Amy, Mukhopadhyay, Arunima, Kuntz, Elodie M., Mitchell, Rebecca, Olivares, Orianne, Ianniciello, Angela, Scott, Mary T., Dunn, Karen, Nicastri, Michael C., Winkler, Jeffrey D., Michie, Alison M., Ryan, Kevin M., Halsey, Christina, Gottlieb, Eyal, Keaney, Erin P., Murphy, Leon O., Amaravadi, Ravi K., Holyoake, Tessa L., Helgason, G. Vignir

“…In chronic myeloid leukemia (CML), tyrosine kinase inhibitor (TKI) treatment induces autophagy that promotes survival and TKI-resistance in leukemic stem cells…”
Get full text